Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director | June 26, 2026 | June 29, 2026 |
| LAVA Therapeutics NVLVTX · Entity 73047 | Director | November 13, 2025 | November 17, 2025 |
| Replimune Group, Inc.REPL · Entity 4707 | Director | April 01, 2026 | April 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2036-06-25 | Direct | 40,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
LAVA Therapeutics NV
Report date November 13, 2025 · Filed November 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 1
1 source rowRow 1 · 2025-11-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Disposed of pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the " Purchase Agreement") in exchange for (i) $1.04 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2035-02-12 | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-13 · Disposition to issuer · Disposed 33,390 · Balance 0 F2: This option was cancelled pursuant to that certain Purchase Agreement in exchange for cash and CVRs (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the " Purchase Agreement") in exchange for (i) $1.04 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share.
F2: This option was cancelled pursuant to that certain Purchase Agreement in exchange for cash and CVRs (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.
Replimune Group, Inc.
Report date April 01, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2036-04-01 | Direct | 44,500 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 44,500 · Balance 44,500 F1: The shares underlying this option vest entirely on April 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest entirely on April 1, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CARGO Therapeutics, Inc.
Report date August 19, 2025 · Filed August 20, 2025
Section 16 reporting ended · disclosed 2025-08-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.35 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2025-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-08-19 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]
F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]
F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.
FIVE PRIME THERAPEUTICS, INC.
Report date April 16, 2021 · Filed April 19, 2021
Section 16 reporting ended · disclosed 2021-04-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.99 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.80 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.27 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-04-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-04-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.
F2: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 29, 2026 20:34 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001456849-26-000002 · form4-06292026_080659.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-25 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 01:09 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 44,500 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001104659-26-040570 · tm2611350-4_4seq1.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 44,500 shares Expires 2036-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2027. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionStock Option (right to buy) · Derivative | 3,169 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001104659-25-120332 · tm2533265-1_4seq1.xml · derivative · entry 3 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,169 shares Expires 2026-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares underlying this stock option vested on January 21, 2016. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 3,169 | $10.40 | $32,957.60 |
DisclosureSEC source: 0001104659-25-120332 · tm2533265-1_4seq1.xml · nonDerivative · entry 2 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 3,169 | $1.75 | $5,545.75 |
DisclosureSEC source: 0001104659-25-120332 · tm2533265-1_4seq1.xml · nonDerivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reporting person exercised the option due to the upcoming expiration date of the option. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:30 UTC | LAVA Therapeutics NV LVTX · Entity 73047 | Disposition to issuerShare Options (Right to Buy) · Derivative | 33,390 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001456849-25-000005 · form4-11172025_041105.xml · derivative · entry 2 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 33,390 shares Expires 2035-02-12 F2 · derivative.exercise_date: This option was cancelled pursuant to that certain Purchase Agreement in exchange for cash and CVRs (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:30 UTC | LAVA Therapeutics NV LVTX · Entity 73047 | Disposition to issuerCommon Shares | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001456849-25-000005 · form4-11172025_041105.xml · nonDerivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the " Purchase Agreement") in exchange for (i) $1.04 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 01:59 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $4.35 | Not disclosed |
DisclosureSEC source: 0001610717-25-000306 · form4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2035-06-17 F1 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · price: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · price: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration. F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 21:40 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001610717-25-000246 · form4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-17 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) the one year anniversary of June 18, 2025 or (ii) the next Annual Meeting following June 18, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 22:23 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 30,550 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001415889-25-017050 · form4-06122025_100609.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,550 Underlying: Common Stock · 30,550 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 00:03 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001104659-25-031831 · tm2511407-7_4seq1.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2035-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2026. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 01:15 UTC | LAVA Therapeutics NV LVTX · Entity 73047 | GrantCommon Shares (Right to Buy) · Derivative | 33,390 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001415889-25-004527 · form4-02182025_080210.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,390 Underlying: Common Shares · 33,390 shares Expires 2035-02-12 F1 · derivative.exercise_date: 100% of the shares underlying the option will vest on February 13, 2026, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 6, 2024 21:50 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 30,550 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001415889-24-015819 · form4-06062024_090644.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,550 Underlying: Common Stock · 30,550 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:31 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | GrantStock Option (Right to Buy) · Derivative | 11,871 | $0.00 Strike: $19.17 | $0.00 |
DisclosureSEC source: 0001610717-24-000303 · form4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,871 Underlying: Common Stock · 11,871 shares Expires 2034-06-03 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 4, 2024 (the "Vesting Commencement Date") or (ii) the next Annual Meeting following June 4, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 20:15 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | GrantStock Option (Right to Buy) · Derivative | 49,265 | $0.00 Strike: $19.89 | $0.00 |
DisclosureSEC source: 0001610717-24-000209 · form4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,265 Underlying: Common Stock · 49,265 shares Expires 2034-04-14 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from April 15, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001104659-24-043255 · tm2410652-8_4seq1.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2034-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2025. Read SEC document |
| May 16, 2023 Filed May 18, 2023 01:06 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001415889-23-008241 · form4-05182023_010514.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2033-05-15 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:03 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 25,200 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041733 · tm2311410-13_4seq1.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,200 Underlying: Common Stock · 25,200 shares Expires 2033-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2024. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:05 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-006517 · form4-06132022_040601.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:12 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042758 · tm2211665-9_4seq1.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2023. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001104659-21-084241 · tm2120371-2_4seq1.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 19:39 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $4.14 | Not disclosed |
DisclosureSEC source: 0001209191-21-027413 · doc4.xml · derivative · entry 5 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 19:39 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Disposition to issuerStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $6.09 | Not disclosed |
DisclosureSEC source: 0001209191-21-027413 · doc4.xml · derivative · entry 4 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 19:39 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $17.27 | Not disclosed |
DisclosureSEC source: 0001209191-21-027413 · doc4.xml · derivative · entry 3 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 19:39 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $29.80 | Not disclosed |
DisclosureSEC source: 0001209191-21-027413 · doc4.xml · derivative · entry 2 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 19:39 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $37.99 | Not disclosed |
DisclosureSEC source: 0001209191-21-027413 · doc4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:11 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046718 · tm2112099d1_4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 21:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 29,842 | $0.00 Strike: $27.45 | $0.00 |
DisclosureSEC source: 0000899243-21-002963 · doc4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,842 Underlying: Common Stock · 29,842 shares Expires 2031-01-19 F1 · derivative.exercise_date: This option shall vest and become exercisable in thirty-six (36) equal monthly installments following the Grant Date. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:48 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001104659-20-133812 · tm2038101-1_4seq1.xml · derivative · entry 5 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,169 Underlying: Common Stock · 40,000 shares Expires 2026-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option vested on January 21, 2016. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:48 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 1,802 | $47.04 | $84,766.08 |
DisclosureSEC source: 0001104659-20-133812 · tm2038101-1_4seq1.xml · nonDerivative · entry 4 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.85 to $47.21. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:48 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 13,523 | $46.22 | $625,033.06 |
DisclosureSEC source: 0001104659-20-133812 · tm2038101-1_4seq1.xml · nonDerivative · entry 3 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,802 F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.85 to $46.84. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:48 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 24,675 | $45.09 | $1,112,595.75 |
DisclosureSEC source: 0001104659-20-133812 · tm2038101-1_4seq1.xml · nonDerivative · entry 2 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,325 F1 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.84 to $45.82. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:48 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 40,000 | $1.75 | $70,000.00 |
DisclosureSEC source: 0001104659-20-133812 · tm2038101-1_4seq1.xml · nonDerivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 15, 2020 17:46 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001209191-20-029829 · doc4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) May 14, 2021 or (ii) the day before the 2021 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 20:31 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001104659-20-042500 · a4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2030-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2021. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 18:11 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001209191-19-036497 · doc4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-09 F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) June 10, 2020 or (ii) the day before the 2020 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:33 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001104659-19-019720 · a4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2029-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2020. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:25 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047458 · a4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2028-07-19 F1 · derivative.exercise_date: This option was granted on July 19, 2018 subject to the completion of the Issuer's initial public offering, which closed on July 24, 2018. 25% of the shares underlying this stock option vest on July 19, 2019 and the remainder of the shares underlying this stock option vest in 24 equal monthly installments thereafter. Read SEC document |
| May 10, 2018 Filed May 14, 2018 19:47 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.27 | $0.00 |
DisclosureSEC source: 0001209191-18-030064 · doc4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-09 F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) May 10, 2019 or (ii) the day before the 2019 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. Read SEC document |
| May 10, 2017 Filed May 12, 2017 16:22 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001209191-17-031943 · doc4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) May 10, 2018 or (ii) the day before the 2018 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.